Difference between revisions of "201709 Clinical Research"
Wayne Kubick (talk | contribs) |
Wayne Kubick (talk | contribs) |
||
Line 66: | Line 66: | ||
:Action: Clinical trial designer creates an application and user interface which allows the sites to search for specific characteristics based upon the protocol inclusion and exclusion criteria, and output a list of candidate patients and their information to downstream applications. | :Action: Clinical trial designer creates an application and user interface which allows the sites to search for specific characteristics based upon the protocol inclusion and exclusion criteria, and output a list of candidate patients and their information to downstream applications. | ||
<!--Who does what? (Use the role names listed above when referring to the participants --> | <!--Who does what? (Use the role names listed above when referring to the participants --> | ||
− | :Precondition: EHR data exists for a significant group of patients. The data must include Demographic information, clinical narrative and clinical data such as problems, medications and lab reports. At least 1 patient meeting all eligibility criteria exists in the EHR database (may be preassigned) a study and subject identifier. The following Eligibility Criteria is listed in the Protocol ABC5236 | + | :Precondition: EHR data exists for a significant group of patients. The data must include Demographic information, clinical narrative and clinical data such as problems, medications and lab reports. At least 1 patient meeting all eligibility criteria exists in the EHR database (may be preassigned) a study and subject identifier. The following Eligibility Criteria is listed in the Protocol ABC5236: |
:1.1 Female Age: 18-70 | :1.1 Female Age: 18-70 | ||
:1.2 Patients that are newly diagnosed with stage I, II or III unilateral Triple Negative Breast Cancer who have not undergone neoadjuvant chemotherapy or undergone definitive breast surgery. | :1.2 Patients that are newly diagnosed with stage I, II or III unilateral Triple Negative Breast Cancer who have not undergone neoadjuvant chemotherapy or undergone definitive breast surgery. |
Revision as of 21:17, 20 July 2017
Track Name
Clinical Research Track
Submitting WG/Project/Implementer Group
Biopharma FHIR project group; TransCelerate Biopharma eSource Work Stream
Justification
This track will continue to further explore the benefits of FHIR for clinical research of new biopharmaceutical experimental treatments, and to increase visibility of FHIR within the biopharmaceutical community. This track advances the use of FHIR resources as eSource data used to pre-populate clinical research case report forms for both regulated and non-regulated clinical research. It will also explore use of PlanDefinition in the context of research protocols. This builds on previous explorations in Connectathon 13-15.
Plans for this connection include participating from at least 5 Pharmaceutical companies, Members of TransCelerate Biopharma, Inc. consortium, who will be bringing programmers from the EDC vendors they work with to manage clinical study databases. A set of 4-8 detailed use case scenarios will be proposed. A challenge grant award will be issued by TransCelerate to the pharma/vendor team that creates the best FHIR solution to meet one or more of the scenarios. This work will inform development of profiles and IGs to support clinical research using FHIR.
Clinical Research studies currently require the redundant entry of clinical data that already typically reside in Meaningful Use conformant EHR systems. EHR data represents original records in electronic format that can be used as eSource and directly imported into clinical research EDC databases so as to improve the quality and consistency of data between EHR and EDC systems and eliminate the need for redundant data entry. Establishing interoperability between EHR and EDC systems to streamline and modernize clinical investigations should improve data accuracy, patient safety, and clinical research efficiency. Given the extreme cost and extended time required for randomized clinical trials, it would be substantially better to utilize EHR source data to directly populate clinical trial databases wherever feasible. The May 2016 FDA draft guidance titled “Use of Electronic Health Record Data in Clinical Investigations” encourages the sponsors of clinical research to use EHR data as noted in the statement below.
FDA encourages sponsors and clinical investigators to work with the entities that control the EHRs, such as health care organizations, to use EHRs and EDC systems that are interoperable. EHRs may be interoperable with EDC systems in a variety of ways depending on supportive technologies and standards. Interoperable technology may involve automated electronic transmission of relevant EHR data to the EDC system. For example, data elements originating in an EHR (e.g., demographics, vital signs, past medical history, past surgical history, social history, medications, adverse reactions) may automatically populate the eCRFs within an EDC system.
Establishing interoperability between EHR and EDC systems to streamline and modernize clinical investigations should improve data accuracy, patient safety, and clinical research efficiency. Given the extreme cost and extended time required for randomized clinical trials, it would be substantially better to utilize EHR source data to directly populate clinical trial databases wherever feasible. The May 2016 FDA draft guidance titled “Use of Electronic Health Record Data in Clinical Investigations” encourages the sponsors of clinical research to use EHR data as noted in the statement below:
"FDA encourages sponsors and clinical investigators to work with the entities that control the EHRs, such as health care organizations, to use EHRs and EDC systems that are interoperable. EHRs may be interoperable with EDC systems in a variety of ways depending on supportive technologies and standards. Interoperable technology may involve automated electronic transmission of relevant EHR data to the EDC system. For example, data elements originating in an EHR (e.g., demographics, vital signs, past medical history, past surgical history, social history, medications, adverse reactions) may automatically populate the eCRFs within an EDC system."
Proposed Track Lead
See Connectathon_Track_Lead_Responsibilities Wayne Kubick (wkubick@hl7.org), Sam Hume (swhume@gmail.com); Geoff Low (glow@mdsol.com); Trisha Simpson (trisha.simpson@ucb.com)
Expected participants
TransCelerate Biopharma, Inc., UCB, Pfizer, GSK, Merck, Lilly, Medidata, Oracle Health Sciences, others
Roles
Please include information here regarding how much advance preparation will be required if creating a client and/or server.
FHIR Client
Support the sending and receiving of clinical research study data: create, read, search and update from a clinical study database system or a patient device.
FHIR Server
Support the sending and receiving of Clinical Research subject and study data from an EHR.
Clinical Trial Designer
Sets up patient matching criteria and identifiers for ResearchStudy and ResearchSubject for a synthetic test study. Creates study database, mappings/interfaces, EDC case report forms with variable mappings to FHIR that will receive EHR patient data for clinical trial subjects. Generate updates from EDC to apply to the EHR.
Data Collector
Queries API to identify patients by Study and Subject identifiers to pull EHR data for demographics, medications and lab data that maps directly to variables on eCRF. Provides data generated by patients to add to study databases or EHRs.
Subject Matter Expert
SME: Creates and tests queries to identify patients who match eligibility criteria for a study or review data.
Scenarios
Scenario 1 Examining EHR patient data for protocol feasibility and clinical trial recruitment for a specific clinical trial
- Scenario Lead: Lisa Morgan, GSK
Objective: Applications that will allow users to query clinical data (ideally both structured and narrative) from source systems, including EMR’s, to find suitable patients for clinical trials. Background: Currently, manual chart review of a patient’s medical record is typically required to identify patients who may be eligible to participate in clinical trials. However, this process is burdensome, expensive and time intensive, and the complexity of the eligibility criteria requires an appropriately skilled individual to review the information, so that clinical information is appropriately matched and interpreted. As well, that same information used to define the eligibility of the patient, must then be redundantly entered into downstream systems manually for data capture.
- Action: Clinical trial designer creates an application and user interface which allows the sites to search for specific characteristics based upon the protocol inclusion and exclusion criteria, and output a list of candidate patients and their information to downstream applications.
- Precondition: EHR data exists for a significant group of patients. The data must include Demographic information, clinical narrative and clinical data such as problems, medications and lab reports. At least 1 patient meeting all eligibility criteria exists in the EHR database (may be preassigned) a study and subject identifier. The following Eligibility Criteria is listed in the Protocol ABC5236:
- 1.1 Female Age: 18-70
- 1.2 Patients that are newly diagnosed with stage I, II or III unilateral Triple Negative Breast Cancer who have not undergone neoadjuvant chemotherapy or undergone definitive breast surgery.
- 1.3 ECOG performance status score of 0-1 (Karnofsky score can be substituted)
- 1.4 Have a Left Ventricular Ejection Fraction (LVEF) of ≥ 50% by echocardiogram or MUGA scan, and does not have a current or historical diagnosis of CHF, MI, TIA, PVD, or uncontrolled hypertension with a blood pressure of greater than 160/90
- 1.5 Subject does not have metastatic disease (consider substituting a positive occurrence rather than an absence of a condition which is more difficult to query).
- Success Criteria: Returns counts, practitioner identifiers, patient identifiers The application will present the research data user with (1) a count of patients that meet the criteria and (2) a list of ranked patients that can be manually validated as eligible for clinical trials ABC5236. The information retrieved will allow a patient to be enrolled and randomized and allow sending of the relevant information on that patient downstream in a machine-readable format for consumption by appropriate application(s).
- Bonus point: Assign a ResearchStudy Identifier and ResearchSubject Identifier in EHR for enrolled subjects
Scenario 2 Extract relevant EHR data for ResearchSubject and import into Study Database
- Action: Identify Patient enrolled in ResearchStudy, extract relevant EHR data, import into EDC Study Database
- Precondition: Patient records include demographics, MedicationStatement, Lab observation data, possibly problems, diagnosis, healthcare utilization data. At least one patient has at least 2 sets of lab observations for at least 3 lab tests. LOINC codes for the set of lab tests to be used and mappings to CDISC for these will be specified in advance.
- Success Criteria: The EHR data is successfully imported into an EDC system for the selected subject.
- Bonus point : Document the mapping of CCDS content to CDISC standard data elements.
- Bonus point 2: identify and extract relevant unstructured data.
Scenario 3 Receive and apply updates to the study database as new or changed data is recorded in the EHR
- Action: Enter new data in EHR for a current ResearchSubject after new patient encounter is recorded in EHR
- Precondition: Patient is enrolled as a ResearchSubject for a ResearchStudy.
- Success Criteria: The updated EHR data is successfully imported into an EDC system for the selected subject.
- Bonus point : Use CDS Hooks to trigger update after patient encounter is recorded.
Scenario 4 Import Patient-generated data into EHR for ResearchStudy
- Action: Import relevant new data in EHR for a current ResearchSubject generated from SMART on FHIR App on mobile device.
- Precondition: Patient is enrolled as a ResearchSubject for a ResearchStudy. SMART on FHIR App relevant to research is identified and able to import data into EHR.
- Success Criteria: The subject data is successfully imported into an EDC system for the selected subject and available for export to Study Database.
- Bonus point :The subject-generated data is successfully imported into Study Database.